Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy

Author： Weart Charles Wayne   Hogan Richard J  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.1, 2011-01, pp. : 99-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Further evidence for BP reduction with statins

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 7, 2007-07 ,pp. : 693-699

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial(Current and Future Options for Lipid-lowering Therapy Beyond Statins)

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3072-3073

Bentham Science Publishers

Access to resources Recommend Favorite

Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases

By  

Current Gene Therapy, Vol. 6, Iss. 1, 2006-02 ,pp. : 45-58

Bentham Science Publishers

Access to resources Recommend Favorite

Combination Therapy for Neuropathic Pain: A Review of Current Evidence

By Vorobeychik Yakov  

CNS Drugs, Vol. 25, Iss. 12, 2011-12 ,pp. : 1023-1034

Adis International

Access to resources Recommend Favorite